Its latest results show that 35% of Americans could not access quality health care if they need it. Rates were even higher ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Lepodisiran is being developed by biotech giant Eli Lilly & Co. (LLY), a stock that’s in my model portfolio. Here’s the tale of this new drug…how it could help millions of heart-ailment sufferers…and ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent.

Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.